About 20% of population deaths are related to infectious diseases, of
which viral infections occupy an important place. According to the World
Health Organization (WHO), 37 million people worldwide are infected with
human immunodeficiency virus (HIV), 257 million with hepatitis B virus
(HBV), 70 million with hepatitis C virus (HCV, viral hepatitis), and 3
to 5 million with influenza each year.
Vaccination is considered to be the best way to protect people from viral
infections. However, vaccines tend to lose their effectiveness quickly
during the rapid evolution of pathogens, so scientists have been searching
for effective antiviral drugs. To date, more than 100 antiviral drugs have
been officially registered, and their number continues to grow at an average
rate of 4-6 new drugs per year.
focuses on the promise of therapeutic proteins in viral diseases, offering
a diverse range of therapeutic proteins, including hepatitis B vaccine
antigen, interferon, etc., to assist researchers in the field of viral
disease treatment and drug development to conduct relevant research and
develop potential therapeutic compounds.
Therapeutic proteins and viral diseases
Immunoglobulins (IG) are produced by the spleen, lymph nodes, and other
lymph plasma cells in tissues that produce globulins that have antibody
activity or are chemically similar to antibodies. Immunoglobulins are also
widely used in various immunodeficiency diseases, autoimmune diseases,
and infectious diseases because of their low side effects and the ability
to increase doses.
In addition to this, scientists are constantly searching for new targets
in the development of drugs for the treatment of viral diseases to inhibit
viral multiplication or to influence the life cycle of the virus. Some
of these drugs affect the host rather than the virus, such as
and their inducers. Interferons have immunomodulatory, antiviral, and
antibacterial functions and, as biologically active secreted proteins,
are major components of the immune system of the animal body.
As research progresses, the physicochemical characteristics, mechanisms
of action, and molecular structures of interferons and immunoglobulins,
which are therapeutic proteins, are becoming clearer, providing a useful
reference for later research on the treatment of viral diseases.
, as a specialist in therapeutic proteins, continues to provide a diverse
range of high-quality therapeutic protein products to researchers in the
field of viral disease treatment and drug development. If you do not find
your target therapeutic protein product in the current category, please
our staff directly for the latest product information.
, (2021). “New Approaches to the Prevention and Treatment of Viral
Archivum Immunologiae et Therapiae Experimentalis
Hemming, V., G., (2001). “Use of Intravenous Immunoglobulins for
Prophylaxis or Treatment of Infectious Diseases.”
Clinical Diagnostic Laboratory Immunology